Back to today’s briefing

Story perspectives

States Confront Financial Crisis Over Soaring GLP-1 Drug Costs

4/14/2025

30 4

Summary

Story summary

States are facing a financial storm as the costs of GLP-1 drugs like Ozempic and Wegovy soar, threatening to strain Medicaid budgets. In response, Pennsylvania and Connecticut are contemplating limits on weight loss coverage. Across the pond, the UK grapples with skyrocketing demand for these medications, even as patients contend with troubling side effects like hair loss and muscle depletion.

1 of 1

Story summary

States are facing a financial storm as the costs of GLP-1 drugs like Ozempic and Wegovy soar, threatening to strain Medicaid budgets. In response, Pennsylvania and Connecticut are contemplating limits on weight loss coverage. Across the pond, the UK grapples with skyrocketing demand for these medications, even as patients contend with troubling side effects like hair loss and muscle depletion.